WindMIL Therapeutics, Inc. logo

WindMIL Therapeutics, Inc.

WindMIL Therapeutics, is a clinical stage company developing bone marrow derived, Marrow-Infiltrating Lymphocytes (MILs_) for cancer immunotherapy to treat solid and liquid cancers.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://windmiltherapeutics.com
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1812 Ashland Avenue, 1st Floor, Suite 100, MD, 21205
Baltimore
United States
Email
Contact Number
+1 410-558-1906

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

In June 2018, WindMIL Therapeutics raised $32.5 Mn in Series B financing led by Qiming Venture Partners USA. Other new investors included Medivate Partners and Camden Partners Nexus. Existing investors Domain Associates and FOXKISER also participated in Series B financing. Earlier in April 2016, WindMIL raised $10 Mn in a series A round led by Domain Associates.